CJC-1295 (No DAC)
Mod GRF 1-29 / Modified GRF (1-29) / Tetrasubstituted GRF 1-29
CJC-1295 without DAC, also sold as Modified GRF (1-29), is GHRH(1-29) with four amino-acid substitutions (D-Ala2, Gln8, Ala15, Leu27) meant to resist breakdown. It lacks the albumin-binding DAC, so it acts briefly and is used for short GH pulses. It is not FDA-approved and has no published human trials.
Half-life
Not established in humans
Typical Dose
100–300 mcg per dose
180/300Route
subcutaneous
Category
growth_hormone
Evidence Overview
Strength of evidence across clinical, expert, and experimental lanes.
How CJC-1295 (No DAC) is dosed in practice
Usually taken by subcutaneous (SubQ) injection. Typical range: 100–300 mcg per dose. Half-life: Not established in humans. Each card gives the dose, frequency and duration from one evidence lane: Clinical (human trials), Expert (practitioner protocols) or Experimental (early or animal data). These ranges describe what has been studied or used; they are not a prescription.
Work out the units to draw with the reconstitution calculator, how long a vial lasts with the vial duration calculator, and how levels fall between doses with the half-life calculator.
Most commonly combined with Ipamorelin (1:1 ratio) for the 'CJC/Ipa' stack. Bedtime dosing is common, timed to the natural nighttime GH rise; pre-workout dosing is used for recovery. Chosen over the DAC version by practitioners who want short GH pulses rather than days-long elevation.
- Practitioner protocols
Unlock Full Evidence Sources
Get complete clinical data, expert protocols, and experimental research for CJC-1295 (No DAC) and 90+ other compounds with Pro.
Upgrade to ProInteraction Network
Known interactions with other compounds. Click nodes to explore connections.
Safety & Contraindications
- Active malignancy
- Pituitary surgery or damage
- Diabetes (monitor glucose closely)
CJC-1295 (No DAC): common questions
What is CJC-1295 (No DAC)?
CJC-1295 without DAC, also sold as Modified GRF (1-29), is GHRH(1-29) with four amino-acid substitutions (D-Ala2, Gln8, Ala15, Leu27) meant to resist breakdown. It lacks the albumin-binding DAC, so it acts briefly and is used for short GH pulses. It is not FDA-approved and has no published human trials.
How is CJC-1295 (No DAC) dosed?
CJC-1295 (No DAC) is usually taken by subcutaneous (SubQ) injection. Typical range in DoseCraft's library: 100–300 mcg per dose. Expert (practitioner protocols): 100–200 mcg per dose (with equal Ipamorelin); 2–3x daily (AM, pre-workout, bedtime); 12 weeks on, 4 weeks off. These ranges describe what has been studied or used; they are not a prescription.
Is CJC-1295 (No DAC) FDA-approved?
No. CJC-1295 (No DAC) is not approved by the FDA for any use in people.
What is the half-life of CJC-1295 (No DAC)?
DoseCraft's library lists a half-life of Not established in humans. Half-life sets how often a compound is dosed and how long it takes to clear: about five half-lives.
Who should not use CJC-1295 (No DAC)?
Listed contraindications: Active malignancy; Pituitary surgery or damage; Diabetes (monitor glucose closely).
Free Guides for CJC-1295 (No DAC)
Information is for educational purposes only. Always consult a licensed healthcare provider before starting any peptide regimen.
Page updated . How we grade evidence: methodology.